The Winds of Change: Emerging Therapeutics in Prostate Cancer

American Society of Clinical Oncology Educational Book
Carmel J PezaroRavi A Madan

Abstract

The last decade has seen substantial advances in androgen receptor targeting in prostate cancer. In addition, advances have been made in immunotherapy and radiopharmaceutical-based therapy, although their optimal use in the clinic remains unclear. Recent understanding of the relevance and actionability of DNA damage repair mutations in a considerable minority of patients with prostate cancer is likely to open up a new frontier in prostate cancer therapeutics. As androgen receptor-directed therapy moves earlier in the disease process for prostate cancer, advances in these nonandrogen receptor-based therapeutics may take on greater significance in the years to come.

References

Jul 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mala ChakrabortyJames W Hodge
Jun 26, 2009·The New England Journal of Medicine·Peter C FongJohann S de Bono
Sep 8, 2010·The New England Journal of Medicine·Philip W KantoffUNKNOWN IMPACT Study Investigators
May 27, 2011·The New England Journal of Medicine·Johann S de BonoUNKNOWN COU-AA-301 Investigators
Aug 17, 2012·The New England Journal of Medicine·Howard I ScherUNKNOWN AFFIRM Investigators
Apr 10, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elena CastroRosalind Eeles
Jul 19, 2013·The New England Journal of Medicine·C ParkerUNKNOWN ALSYMPCA Investigators
Nov 26, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Peter Bouwman, Jos Jonkers
Nov 28, 2014·Oncotarget·Jennifer L BishopAmina Zoubeidi
May 23, 2015·Cell·Dan RobinsonArul M Chinnaiyan
Oct 29, 2015·The New England Journal of Medicine·Joaquin MateoJohann S de Bono
Nov 19, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J N GraffC N Sternberg
Jan 19, 2016·Nature Reviews. Cancer·Christopher J Lord, Alan Ashworth
Jan 23, 2016·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Richard P BaumHans-Jürgen Wester
Mar 18, 2016·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Clemens KratochwilUwe Haberkorn
May 28, 2016·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Ana P KiessMartin G Pomper
Jul 20, 2016·The New England Journal of Medicine·Colin C PritchardPeter S Nelson
Oct 4, 2016·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Harshad R KulkarniRichard P Baum
Oct 9, 2016·The New England Journal of Medicine·Mansoor R MirzaUNKNOWN ENGOT-OV16/NOVA Investigators
Oct 22, 2016·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Kambiz RahbarBernd Joachim Krause
Dec 31, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tomasz M BeerWinald Gerritsen
Mar 18, 2017·Science·Christopher J Lord, Alan Ashworth
Apr 2, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mari I SuominenArne Scholz
Apr 19, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J MateoJ S de Bono
Jun 6, 2017·The New England Journal of Medicine·Mark RobsonPierfranco Conte
Jul 1, 2017·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Wolfgang P FendlerMatthias Eiber
Aug 3, 2017·European Journal of Nuclear Medicine and Molecular Imaging·Sara SheikhbahaeiSteven P Rowe
Aug 19, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher P ChildersJames Macinko
Aug 19, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kevin S Hughes
Oct 12, 2017·The New England Journal of Medicine·Steven LemeryRichard Pazdur
Dec 1, 2017·The Oncologist·Oliver SartorUNKNOWN U.S. Expanded Access Program Investigators
Dec 21, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maha HussainArul M Chinnaiyan

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Current Oncology Reports
Daniel W Sonnenburg, Alicia K Morgans
Advances in Experimental Medicine and Biology
Brian G BarnettTyler J Curiel
Telemedicine Journal and E-health : the Official Journal of the American Telemedicine Association
Charles R Doarn, Ronald C Merrell
The Journal of the American Association of Gynecologic Laparoscopists
David L Olive
Scientific American
Jeremy Hsu
© 2022 Meta ULC. All rights reserved